 Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, the company announced that it has hit 100 MACE-4 accumulation. The companys mixed earnings were only a slight improvement over Q1. I was expecting the market to punish ESPR, but it appears the possibility of a Q1 readout offset. 